Answers are grounded in this paper and cite their sources.
Analysis reveals high HIV-1 suppression with dolutegravir/lamivudine in adults with hepatitis B implications.
This analysis provides new information about DTG/3TC treatment for people with HIV-1 and isolated reactive anti-HBc. There were high rates of HIV-1 suppression with DTG/3TC, no cases of HBV reactivation and no new safety signals identified.
No takes yet. Share an insight, caveat, or question.
Fox et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: